59.91
Kymera Therapeutics Inc Aktie (KYMR) Neueste Nachrichten
Decoding Kymera Therapeutics Inc (KYMR): A Strategic SWOT Insigh - GuruFocus
Is Kymera Therapeutics Inc. stock supported by innovation pipeline2025 Dividend Review & Real-Time Market Trend Scan - newser.com
Kymera Therapeutics Reports Q3 2025 Financial Results - TipRanks
Kymera Therapeutics’ Earnings Call Highlights Growth and Challenges - TipRanks
Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (KYMR), Cullinan Management (CGEM) and Idexx Laboratories (IDXX) - The Globe and Mail
Kymera outlines mid-2027 topline readout for KT-621 Phase IIb study as pipeline advances and Gilead partnership grows - MSN
Transcript : Kymera Therapeutics, Inc., Q3 2025 Earnings Call, Nov 04, 2025 - MarketScreener
Kymera Therapeutics Q3 2025 Earnings Call Transcript - MarketBeat
Oppenheimer raises Kymera Therapeutics stock price target ahead of Phase 1b readout - Investing.com Canada
Earnings call transcript: Kymera Therapeutics Q3 2025 misses EPS expectations - Investing.com Philippines
Kymera Q3 2025 slides reveal strong cash position despite earnings miss - Investing.com
Kymera Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Kymera Therapeutics Announces Third Quarter 2025 Financial Results and Provides a Business Update - Investing News Network
Earnings Flash (KYMR) Kymera Posts Q3 Loss $0.94 a Share, vs. FactSet Est of $0.68 Loss - MarketScreener
Earnings Flash (KYMR) Kymera Therapeutics, Inc. Reports Q3 Revenue $2.8M, vs. FactSet Est of $23.3M - MarketScreener
Kymera Therapeutics Inc Q3 2025 Earnings: EPS of -$0.94 Misses E - GuruFocus
Kymera Therapeutics (NASDAQ:KYMR) Coverage Initiated by Analysts at Guggenheim - MarketBeat
Kymera Therapeutics (NASDAQ: KYMR) completes AD Phase 1b dosing, starts Phase 2b trial - Stock Titan
Kymera Therapeutics Q3 2025 Earnings Preview - MSN
Pattern recognition hints at Kymera Therapeutics Inc. upsideJuly 2025 Opening Moves & Expert Curated Trade Setups - newser.com
Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025 - Investing News Network
Guggenheim Assumes Buy Rating for Kymera Therapeutics (KYMR) | K - GuruFocus
Kymera Therapeutics Inc (KYMR) Q3 2025 Earnings Report Preview: What to Look For - GuruFocus
How to read the order book for Kymera Therapeutics Inc.Portfolio Growth Summary & Consistent Profit Focused Trading Strategies - newser.com
Kymera Therapeutics to Participate in Upcoming November Investor Conferences - The Manila Times
Guggenheim assumes coverage on Kymera stock with Buy rating, $90 target - Investing.com Canada
Kymera Therapeutics (NASDAQ: KYMR) to join 5 November investor conferences; webcasts - Stock Titan
How analysts rate Kymera Therapeutics Inc. stock today2025 Year in Review & Stock Portfolio Risk Control - newser.com
What valuation multiples suggest for Kymera Therapeutics Inc. stock2025 Macro Impact & Weekly Chart Analysis and Guides - newser.com
AlphaQuest LLC Acquires New Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat
34,797 Shares in Kymera Therapeutics, Inc. $KYMR Bought by Moody Aldrich Partners LLC - MarketBeat
Is Kymera Therapeutics Inc. stock attractive for ETFsWeekly Stock Report & Weekly Breakout Opportunity Watchlist - newser.com
Jennison Associates LLC Acquires 272,739 Shares of Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics Inc expected to post a loss of 81 cents a shareEarnings Preview - TradingView
Kymera Therapeutics (NASDAQ:KYMR) CEO Sells $1,829,700.00 in Stock - MarketBeat
How hedge fund analytics apply to Kymera Therapeutics Inc. stockJuly 2025 Momentum & Accurate Trade Setup Notifications - newser.com
Is Kymera Therapeutics Inc. meeting your algorithmic filter criteriaJuly 2025 Pullbacks & AI Forecasted Entry and Exit Points - newser.com
Kymera Therapeutics Insider Sold Shares Worth $1,829,737, According to a Recent SEC Filing - MarketScreener
KYMR insider trade: CEO option exercise and matching share sales - Stock Titan
Kymera Therapeutics (KYMR): Assessing Valuation Following Promising Preclinical Data for KT-579 in Autoimmune Diseases - Yahoo Finance
How Investors Are Reacting To Kymera Therapeutics (KYMR) Preclinical Data on Oral IRF5 Degrader in Lupus and RA - Yahoo Finance
Is Kymera Therapeutics Inc. stock undervalued vs historical averagesJuly 2025 Earnings & Low Volatility Stock Recommendations - fcp.pa.gov.br
Kymera Therapeutics to Announce Q3 2025 Financial Results and Host Video Conference on November 4, 2025 - Quiver Quantitative
Kymera Therapeutics (NASDAQ: KYMR) to report third quarter 2025; webcast at 8:30 a.m. ET - Stock Titan
What technical charts say about Kymera Therapeutics Inc. stockJuly 2025 Summary & Community Verified Trade Signals - Fundação Cultural do Pará
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):